Venpa
Generic Name
Venlafaxine
Manufacturer
Eskayef Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| venpa 50 mg capsule | ৳ 14.00 | ৳ 140.00 |
Description
Overview of the medicine
Venpa 50 mg capsule contains Venlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.
Uses & Indications
Dosage
Adults
For MDD, typically 75 mg/day in 2-3 divided doses (immediate-release) or once daily (extended-release), titrating up to 150-225 mg/day as needed. 50 mg may be a starting dose or for specific patient groups.
Elderly
Lower starting doses and slower titration may be advisable, monitoring for adverse effects.
Renal_impairment
Dosage reduction is recommended; e.g., 25-50% reduction for moderate to severe impairment.
How to Take
Take orally, generally with food. Capsules should be swallowed whole; do not crush, chew, or open.
Mechanism of Action
Venlafaxine enhances neurotransmission of serotonin and norepinephrine in the central nervous system by blocking their reuptake into presynaptic neurons. It also weakly inhibits dopamine reuptake.
Pharmacokinetics
Onset
Clinical effects may take 2-4 weeks to become apparent.
Excretion
Excreted primarily in the urine as venlafaxine, ODV, and other minor metabolites.
Half life
Venlafaxine: approximately 5 hours; O-desmethylvenlafaxine (active metabolite): approximately 11 hours.
Absorption
Well absorbed after oral administration, with peak plasma concentrations occurring within 2-4 hours for immediate-release formulations.
Metabolism
Extensively metabolized in the liver, primarily by CYP2D6 to O-desmethylvenlafaxine (ODV) and by CYP3A4 to N-desmethylvenlafaxine.
Side Effects
Contraindications
- Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI
- Hypersensitivity to venlafaxine or any component of the formulation
Drug Interactions
MAOIs
Risk of serotonin syndrome (potentially fatal).
Warfarin
Potentiation of anticoagulant effects, increased bleeding risk.
Cimetidine
May inhibit first-pass metabolism of venlafaxine, especially in poor metabolizers of CYP2D6.
SSRIs/SNRIs/Triptans
Increased risk of serotonin syndrome.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms may include somnolence, mild tachycardia, nausea, vomiting, dizziness, mydriasis, seizures, and ECG changes. Management involves symptomatic and supportive care; there is no specific antidote.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Not recommended during breastfeeding as venlafaxine and its active metabolite are excreted into breast milk.
Side Effects
Contraindications
- Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI
- Hypersensitivity to venlafaxine or any component of the formulation
Drug Interactions
MAOIs
Risk of serotonin syndrome (potentially fatal).
Warfarin
Potentiation of anticoagulant effects, increased bleeding risk.
Cimetidine
May inhibit first-pass metabolism of venlafaxine, especially in poor metabolizers of CYP2D6.
SSRIs/SNRIs/Triptans
Increased risk of serotonin syndrome.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms may include somnolence, mild tachycardia, nausea, vomiting, dizziness, mydriasis, seizures, and ECG changes. Management involves symptomatic and supportive care; there is no specific antidote.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Not recommended during breastfeeding as venlafaxine and its active metabolite are excreted into breast milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from manufacturing date
Availability
Pharmacies, hospitals
Approval Status
Approved (e.g., FDA, DGDA)
Patent Status
Generic available
Clinical Trials
Extensive clinical trials have demonstrated venlafaxine's efficacy in major depressive disorder and various anxiety disorders. Ongoing research explores its use in other conditions.
Lab Monitoring
- Monitor blood pressure regularly, especially during initial treatment and dose escalation. Monitor serum sodium levels, especially in elderly patients.
Doctor Notes
- Caution with patients having a history of cardiovascular disease or hypertension.
- Monitor for signs of serotonin syndrome, especially when used with other serotonergic agents.
- Advise patients on the importance of adherence and not stopping abruptly.
Patient Guidelines
- Do not stop taking this medicine abruptly without consulting your doctor, as withdrawal symptoms may occur.
- Take consistently at the same time each day.
- Report any worsening depression or suicidal thoughts to your doctor immediately.
Missed Dose Advice
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose.
Driving Precautions
May cause dizziness, somnolence, or blurred vision. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that venlafaxine does not adversely affect their ability to engage in such activities.
Lifestyle Advice
- Avoid alcohol consumption.
- Engage in regular physical activity to help manage mood.
- Maintain a healthy diet and adequate sleep.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Venpa Brand
Other medicines available under the same brand name
